Anticipating Heron Therapeutics' Breakout on Phase 3 Results
AI Prediction of Heron Therapeutics, Inc. (HRTX)
Heron Therapeutics, with its robust pipeline and strong R&D focus, is poised for potential growth driven by upcoming catalysts, including a major Phase 3 clinical trial result. The company's strategic focus on pharmaceutical preparations positions it well in the biotech sector for a potential breakout.
HRTX Report Information
Prediction Date2025-07-03 04:45:57
Close @ Prediction$2.20
Mkt Cap330m
IPO Date1987-08-27
AI-derived Information
Recent News for HRTX
- Aug 15 — Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value (PR Newswire)
- Aug 9 — Heron Therapeutics Inc (HRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
- Aug 8 — Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
- Aug 8 — Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
- Aug 8 — Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
- Aug 8 — Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile (PR Newswire)
- Aug 8 — Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress (PR Newswire)
- Aug 8 — Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 (PR Newswire)
- Jul 29 — Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 (PR Newswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.